Cell-permeable, non-peptide inhibitor of X-linked inhibitor of apoptosis (XIAP) (IC50 = 4.1 μM in competition binding assay with Smac peptide); binds to the BIR3 domain, preventing XIAP interaction with caspase-9 and Smac. Inhibits cell growth, induces apoptosis and activates caspase-9 in prostate cancer cells (IC50 4 - 6 μM), but has a weaker effect on normal prostate cells (IC50 = 19 - 20 μM). Overcomes the protective effect of XIAP on apoptosis in XIAP-transfected Jurkat cells. Anti-tumor, analgesic and anti-inflammatory in vivo.